Jennifer Gori, PhD

Obsidian Therapeutics, Inc., Associate Director in Cell Therapy, Head of Pharmacology


What is your current professional status?

Associate Director in Cell Therapy, Head of Pharmacology

What is your work setting?

Biotechnology Company

What is your scientific area of research?

Gene editing, gene and cell therapy

Why do you want to be a mentor?

I like to instill confidence and enthusiasm for scientific discovery in other scientists. I also hope to empower them to clarify their goals, and provide support so that they feel prepared to confidently and strategically pursue their goals.

As a mentor, what are you hoping to gain from this experience?

I hope to provide perspective on how one can shape their own career path. There are many exciting opportunities in different types of organizations, with varied responsibilities and scientific disciplines to be learned, harnessed, and applied to the clinic. As someone who has held different positions in both academic and industrial settings, I've learned how to merge my interests and expertise with jobs and work environments that are mutually beneficial to myself and the organization, in a shared goal to develop new therapies for patients.

Summarize in a brief paragraph (150 words or less), please provide a biography that describes who you are and what you do in the field of gene and/or cell therapy:

  • Compatibility of Scientific Specialties: 3
  • Geographic Location: 4
  • Professional Status / Success: 5 (least)
  • Compatibility of Career Path: 1 (most)
  • Communication Style: 2

Summarize in a brief paragraph (150 words or less), please provide a biography that describes who you are and what you do in the field of gene and/or cell therapy:

Jennifer Gori is currently Associate Director in Cell Therapy and Head of Pharmacology at Obsidian Therapeutics, a biotechnology company that is building gene and cell therapies with pharmacologic operating systems to provide precise control over engineered cells. In 2014, as one of the first scientists to join Editas Medicine, she strategically planned hematopoietic cell therapy programs and led a dynamic cross-functional team focused on the development and application of CRISPR nuclease-mediated gene editing of hematopoietic stem cells for the treatment of Sickle Cell Disease and immunodeficiencies.

Dr. Gori has more than 15 years of experience in hematopoietic stem cell and lymphocyte gene editing, gene therapy and cell therapy, generation of engineered blood cells from pluripotent stem cells, and hematopoietic stem cell transplantation. Prior to joining Editas Medicine, Dr. Gori was an Associate in Clinical Research in the Clinical Research Division at the Fred Hutchinson Cancer Research Center. At the Hutch, Dr. Gori focused on in vivo preclinical translation of lentivirus modified hematopoietic stem cell and T cell therapies and generation of hematopoietic stem cells from induced pluripotent stem cells. Dr. Gori received her PhD in Microbiology, Immunology, and Cancer Biology in 2008 from the University of Minnesota where she studied lentiviral gene therapy in hematopoietic stem cells and generation of hematopoietic cells for cell therapy from pluripotent stem cells.  

View CV

2019
ASGCT Policy Summit
November 4 – 6 | Washington D.C.
Close